Stockreport

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Reported EPS is $-0.84, expectations were $-0.88. RLMD isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here [Read more]